JP2018511555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511555A5 JP2018511555A5 JP2017538667A JP2017538667A JP2018511555A5 JP 2018511555 A5 JP2018511555 A5 JP 2018511555A5 JP 2017538667 A JP2017538667 A JP 2017538667A JP 2017538667 A JP2017538667 A JP 2017538667A JP 2018511555 A5 JP2018511555 A5 JP 2018511555A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- modified oligonucleotide
- wing segment
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 15
- 239000002777 nucleoside Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000003835 nucleoside group Chemical group 0.000 claims 8
- 239000003638 chemical reducing agent Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 206010053857 partial lipodystrophy Diseases 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229960004042 diazoxide Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 238000010448 genetic screening Methods 0.000 claims 1
- 230000010030 glucose lowering effect Effects 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 0 C*OC1C2(CO*)OC(*)C1***21CC1 Chemical compound C*OC1C2(CO*)OC(*)C1***21CC1 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126439P | 2015-02-27 | 2015-02-27 | |
| US62/126,439 | 2015-02-27 | ||
| PCT/US2016/019728 WO2016138355A1 (en) | 2015-02-27 | 2016-02-26 | Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018511555A JP2018511555A (ja) | 2018-04-26 |
| JP2018511555A5 true JP2018511555A5 (enExample) | 2020-06-18 |
Family
ID=56789093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538667A Pending JP2018511555A (ja) | 2015-02-27 | 2016-02-26 | リポジストロフィー集団におけるアポリポタンパク質Ｃ−ＩＩＩ（ＡｐｏＣＩＩＩ）発現の調節 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180245076A1 (enExample) |
| EP (1) | EP3270931A4 (enExample) |
| JP (1) | JP2018511555A (enExample) |
| KR (1) | KR20170122769A (enExample) |
| CN (1) | CN107405358A (enExample) |
| AU (1) | AU2016222548A1 (enExample) |
| BR (1) | BR112017015307A2 (enExample) |
| CA (1) | CA2977971A1 (enExample) |
| HK (1) | HK1248522A1 (enExample) |
| IL (1) | IL253346A0 (enExample) |
| MX (1) | MX2017011009A (enExample) |
| RU (1) | RU2737719C2 (enExample) |
| WO (1) | WO2016138355A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019002818A (es) * | 2016-09-12 | 2019-08-29 | Aegerion Pharmaceuticals Inc | Metodos para detectar anticuerpos neutralizantes anti-leptina. |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| WO2022072244A1 (en) * | 2020-10-02 | 2022-04-07 | Ionis Pharmaceuticals, Inc. | Methods for reducing apociii expression |
| JP2024525800A (ja) * | 2021-07-16 | 2024-07-12 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| PL2670486T3 (pl) * | 2011-01-31 | 2016-08-31 | Cadila Healthcare Ltd | Leczenie lipodystrofii |
| UA115309C2 (uk) * | 2011-04-27 | 2017-10-25 | Іоніс Фармасьютікалз, Інк. | Модуляція експресії аполіпопротеїну ciii (apociii) |
| DK2956176T3 (en) * | 2013-02-14 | 2018-08-27 | Ionis Pharmaceuticals Inc | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS |
| US9909124B2 (en) * | 2013-06-21 | 2018-03-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile |
| US20150045431A1 (en) * | 2013-08-06 | 2015-02-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy |
-
2016
- 2016-02-26 KR KR1020177025758A patent/KR20170122769A/ko not_active Ceased
- 2016-02-26 US US15/553,946 patent/US20180245076A1/en not_active Abandoned
- 2016-02-26 AU AU2016222548A patent/AU2016222548A1/en not_active Abandoned
- 2016-02-26 BR BR112017015307A patent/BR112017015307A2/pt not_active Application Discontinuation
- 2016-02-26 HK HK18107740.8A patent/HK1248522A1/zh unknown
- 2016-02-26 CN CN201680009110.1A patent/CN107405358A/zh active Pending
- 2016-02-26 RU RU2017133142A patent/RU2737719C2/ru active
- 2016-02-26 JP JP2017538667A patent/JP2018511555A/ja active Pending
- 2016-02-26 CA CA2977971A patent/CA2977971A1/en not_active Abandoned
- 2016-02-26 MX MX2017011009A patent/MX2017011009A/es unknown
- 2016-02-26 EP EP16756424.4A patent/EP3270931A4/en not_active Withdrawn
- 2016-02-26 WO PCT/US2016/019728 patent/WO2016138355A1/en not_active Ceased
-
2017
- 2017-07-06 IL IL253346A patent/IL253346A0/en unknown
-
2019
- 2019-07-31 US US16/528,387 patent/US20200095581A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516516A5 (enExample) | ||
| JP2020111594A5 (enExample) | ||
| JP2016513110A5 (enExample) | ||
| RU2015151200A (ru) | Композиции и способы модулирования экспрессии аполипопротеина (а) | |
| JP2014513954A5 (enExample) | ||
| JP2016533717A5 (enExample) | ||
| JP2018511555A5 (enExample) | ||
| JP6203707B2 (ja) | アポリポタンパク質ｃｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 | |
| JP2014511686A5 (enExample) | ||
| JP2017510271A5 (enExample) | ||
| JP2005503142A5 (enExample) | ||
| JP2017505116A5 (enExample) | ||
| JP2014530004A5 (enExample) | ||
| JP6313789B2 (ja) | リポタンパク質リパーゼ欠損（ｌｐｌｄ）集団におけるアポリポタンパク質ｃ−ｉｉｉ（ａｐｏｃｉｉｉ）発現の調節 | |
| JP2016522817A5 (enExample) | ||
| JP2013526860A5 (enExample) | ||
| JP2020022483A5 (enExample) | ||
| JP2020511155A5 (enExample) | ||
| JP2016171800A5 (enExample) | ||
| JP2016528891A5 (enExample) | ||
| JP2013538560A5 (enExample) | ||
| IL264288B (en) | Methods and compositions for modulating apolipoprotein(a) expression | |
| EA029137B1 (ru) | Модулирование экспрессии вируса гепатита в (hbv) | |
| JP2013518603A5 (enExample) | ||
| JP2015536132A5 (enExample) |